In a significant update for the Hereditary Angioedema (HAE) community, Argo Biopharmaceutical has announced positive Phase II interim results for BW-20805, its investigational siRNA therapeutic. The data, presented as a late-breaking abstract at the 2026 AAAAI Annual Meeting, highlights the drug’s potential as a “best-in-class” long-acting prophylactic.
I’m seeing a clear shift in the HAE treatment landscape here. While current therapies often require frequent dosing, BW-20805 is aiming for a twice-yearly (Q24W) dosing schedule, which could drastically reduce the treatment burden for patients.
Key Data Highlights: Near-Total Attack Reduction
The open-label study (Poster ID: L42) demonstrated that BW-20805 provides rapid and profound suppression of plasma prekallikrein (PKK) levels—the key driver of HAE attacks.
- Attack-Free Status: An impressive 80% of treated patients (8 out of 10) remained entirely attack-free as of the data cut-off.
- 100% Reduction: In the 600 mg group (dosed every 24 weeks), the time-normalized HAE attack rate decreased by 100%.
- Sustained PKK Suppression: Plasma PKK levels dropped by 97–98% and stayed at those levels for at least 169 days, supporting the potential for a six-month dosing interval.
- Safety Profile: The treatment was generally well-tolerated. I’m noting only mild, transient injection-site reactions and zero serious adverse events.
Why It Matters: The PKK Target
HAE is a rare genetic disorder characterized by sudden, life-threatening swelling. Historically, patients relied on frequent C1 inhibitor replacements or daily oral meds.
BW-20805 works by silencing the PKK gene in the liver using RNA interference (siRNA). By preventing the production of PKK, it stops the cascade that leads to painful swelling before it even starts.
| Feature | BW-20805 (Phase II) | Current Standard Prophylactics |
| Dosing Frequency | Every 3 to 6 months | Daily to Bi-weekly |
| Method | Subcutaneous Injection | Oral, Subcutaneous, or IV |
| Primary Target | Prekallikrein (siRNA) | Kallikrein or C1 Inhibitor |
| Attack Reduction | Up to 100% (High Dose) | Varies (Typically 70-90%) |
What’s Next for BW-20805?
Dr. Dongxu Shu, CEO of Argo Biopharma, stated that these results support further evaluation of the Q6M (every six months) dosing regimen. This would put BW-20805 in direct competition with other long-acting RNA-targeted therapies like donidalorsen, but with a potentially more convenient schedule.
“The selection of our Phase II interim data… highlights its potential to deliver remarkable, sustained reductions in HAE attack rates… and supports further evaluation of a potentially best-in-class dosing regimen.” — Dr. Dongxu Shu, CEO, Argo Biopharma
Editorial Disclosure: This article combines final reporting with the required disclosure. This report is for informational purposes only and is based on a press release from Argo Biopharmaceutical Co., Ltd. as of February 25, 2026. This content does not constitute medical or investment advice. Clinical trial results are interim and subject to change upon completion of the full study. Please read our full Disclaimer.
